A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

Autor:	Scott H. Kaufmann, Ayalew Tefferi, Terra L. Reeder, Animesh Pardanani, Leigh A. Gray, Michelle A. Elliott, Ruben A. Mesa, Georgene Schroeder, Chin Yang Li, Jerome B. Zeldis, Gregory A. Wiseman, David P. Steensma
Rok vydání:	2003
Předmět:	Male medicine.medical_specialty Antineoplastic Agents Hormonal Pancytopenia Anemia medicine.drug_class medicine.medical_treatment Immunology Angiogenesis Inhibitors Biochemistry Gastroenterology Adrenal Cortex Hormones Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Myelofibrosis Adverse effect Aged Chemotherapy business.industry Cell Biology Hematology Middle Aged medicine.disease Thalidomide Surgery Treatment Outcome Tolerability Primary Myelofibrosis Hematopoiesis Extramedullary Splenomegaly Technetium Tc 99m Sulfur Colloid Corticosteroid Female business medicine.drug
Zdroj:	Blood. 101:2534-2541
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood-2002-09-2928
Popis:	Single-agent thalidomide (THAL) at “conventional” doses (> 100 mg/d) has been evaluated in myelofibrosis with myeloid metaplasia (MMM) based on its antiangiogenic properties and the prominent neoangiogenesis that occurs in MMM. THAL monotherapy at such doses produces approximately a 20% response rate in anemia but is poorly tolerated (an adverse dropout rate of > 50% in 3 months). To improve efficacy and tolerability, we prospectively treated 21 symptomatic patients (hemoglobin level
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613e3edf0a61a089e39a1c86dd2c97f0 https://doi.org/10.1182/blood-2002-09-2928 Zobrazit plný text záznamu